| Issue Date | Title | Author(s) |
| 2018 | Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial | Li, Jin; Qin, Shukui; Xu, Rui-Hua; Shen, Lin; Xu, Jianming; Bai, Yuxian; Yang, Lei; Deng, Yanhong; Chen, Zhen-dong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Fan, Songhua; Hua, Ye; Su, Weiguo |
| 2018 | A multi-center survey on dietary knowledge and behavior among inpatients in oncology department | Cong, Minghua; Wang, Jiejun; Fang, Yu; Liu, Yinghua; Sun, Mingxiao; Wu, Qiong; Wang, Kan; Huang, Yan; Ling, Yiqun; Liu, Yong; Li, Quanfu; Liu, Yibing; Zhu, Jiang; Zhu, Lingjun; Zheng, Zhendong; Li, Ling; Liu, Dongying; Liu, Zimin; Shi, Hanping; Yuan, Peng |
| 2014 | Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial | Zhang, Xiaotian; Xu, Jianming; Liu, Huilong; Yang, Lin; Liang, Jun; Xu, Nong; Bai, Yuxian; Wang, Jiejun; Shen, Lin |
| 2021 | Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer | Qin, Shukui; Xu, Rui-Hua; Shen, Lin; Xu, Jianming; Bai, Yuxian; Yang, Lei; Deng, Yanhong; Chen, Zhen-dong; Zhong, Haijun; Pan, Hongming; Guo, Weijian; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Wang, Ning; Zhang, Bin; Zhang, Qiang; Su, Weiguo; Guo, Xiaojun; Li, Jin |
| Dec-2020 | Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial | Xu, Ruihua; Qin, Shukui; Guo, Weijian; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Shu, Yongqian; Yuan, Ying; Zhou, Jianfeng; Xu, Nong; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Xu, Jianming; Chen, Donghui; Li, Wei; Sun, Sanyuan; Yu, Zhuang; Cao, Peiguo; Li, Jian; Chen, Haihui; Wang, Jiejun; Wang, Shubin; Wang, Hongbing; Wang, Ning; Zhang, Bin; Han, Rubing; Su, Weiguo; Guo, Xiaojun; Li, Jin |
